Tumor derived PCs inhibit CD4+ T cell proliferation and activation while promoting CD4+ T cell anergy in vitro, which is also regulated by RGS5- and IL-6-dependent signaling pathways (Figure 1, process ➃). Here, IL6 is linked to neoplasm.